We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

19 hedge funds and large institutions have $27M invested in Summit Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

11% more capital invested

Capital invested by funds: $24.3M → $27M (+$2.67M)

0.11% less ownership

Funds ownership: 2.44% → 2.33% (-0.11%)

5% less funds holding

Funds holding: 20 → 19 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
19
Holders Change
-1
Holders Change %
-5%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
JP Morgan Chase
JP Morgan Chase
New York
+$5.42M
2
PC
Polar Capital
United Kingdom
+$1.73M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$1.29M
4
Morgan Stanley
Morgan Stanley
New York
+$313K
5
MFS
Mirabella Financial Services
United Kingdom
+$126K

Top Sellers

1
LPU
Lansdowne Partners (UK)
United Kingdom
-$7.92M
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$428K
3
Renaissance Technologies
Renaissance Technologies
New York
-$200K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$146K
5
CIP
Cornerstone Investment Partners
Georgia
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
1
Polar Capital
United Kingdom
$17.2M +$1.73M +500,000 +11%
JP Morgan Chase
2
JP Morgan Chase
New York
$5.48M +$5.42M +1,565,086 New
Baillie Gifford & Co
3
Baillie Gifford & Co
United Kingdom
$1.28M +$1.29M +372,261 New
Renaissance Technologies
4
Renaissance Technologies
New York
$1.04M -$200K -57,700 -16%
Morgan Stanley
5
Morgan Stanley
New York
$723K +$313K +90,481 +76%
UBS Group
6
UBS Group
Switzerland
$485K +$49.4K +14,268 +11%
BP
7
BBR Partners
New York
$172K – – –
MFS
8
Mirabella Financial Services
United Kingdom
$125K +$126K +36,380 New
Wells Fargo
9
Wells Fargo
California
$120K +$17.9K +5,170 +17%
HSBC Holdings
10
HSBC Holdings
United Kingdom
$94K -$428K -123,633 -82%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$66K – – –
HF
12
HRT Financial
New York
$62K +$62.7K +18,119 New
IC
13
Inscription Capital
Texas
$58K – – –
CAPTRUST Financial Advisors
14
CAPTRUST Financial Advisors
North Carolina
$37K – – –
ASN
15
Advisory Services Network
Georgia
$26K +$26.3K +7,600 New
Bank of America
16
Bank of America
North Carolina
$10K – – –
APA
17
American Portfolios Advisors
New York
$3.44K – – –
Citigroup
18
Citigroup
New York
$1K – – –
Group One Trading
19
Group One Trading
Illinois
$1K – – –
LPU
20
Lansdowne Partners (UK)
United Kingdom
– -$7.92M -2,667,350 Closed
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
– -$146K -49,257 Closed
CIP
22
Cornerstone Investment Partners
Georgia
– -$103K -34,825 Closed
M&T Bank
23
M&T Bank
New York
– -$74K -25,000 Closed
CCA
24
Checchi Capital Advisers
California
– -$59K -20,000 Closed

SMMT Hedge Fund Activity: Q3 2020 in Review

19 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2020, worth a combined $27M — up 11% from $24.3M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SMMT and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $5.42M. The largest seller was Lansdowne Partners (UK), exiting entirely with an estimated $7.92M sold.

  • 19 institutional investors held Summit Therapeutics (SMMT) as of Q3 2020, down from 20 in Q2 2020.
  • Funds reported $27M of Summit Therapeutics stock for Q3 2020, up 11% quarter-over-quarter.
  • 5 funds opened new Summit Therapeutics positions in Q3 2020 and 6 closed out, a net change of -1 holder.
  • The largest Summit Therapeutics buyer in Q3 2020 was JP Morgan Chase, an estimated $5.42M added.
  • The largest Summit Therapeutics seller in Q3 2020 was Lansdowne Partners (UK), an estimated $7.92M sold.

Based on aggregated 13F filings for Q3 2020.